IDH1 and neoplasm: Further development of compound 1 yielded AGI-5198 (Compound 2), the first reported mutant IDH1 inhibitor that showed robust in vivo reduction of D-2HG levels in U87 R132H and HT1080 R132C cell lines and in U87 R132H tumor xenograft model [119].